Experimental combo therapy aims to outsmart leukemia without dangerous side effects

NCT ID NCT05507827

Ongoing Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) along with a special stem cell transplant (Orca-T) is safe for adults with a high-risk type of leukemia called B-cell ALL. The approach is designed to help the donor cells attack the leukemia while reducing the chance of the donor cells attacking the patient's body. The study involves 22 participants and focuses on safety and engraftment success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor-derived CD19/CD22-CAR T cells and Orca-T (regulatory T cells plus stem cells)
What this could lead to: If it works, this could offer a new way to treat B-cell ALL by boosting the immune system's ability to fight leukemia while reducing the risk of graft-versus-host disease.
What could go wrong: This is a very early (Phase 1) and small trial (22 people), so safety and effectiveness are not yet proven. There are risks of severe side effects from the chemotherapy, graft failure, or serious immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia lymphoid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOID LEUKEMIA

Contacts and locations

Locations

Stanford Cancer Center

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.